Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Genkore Inc. currently faces 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are being handled by 3 distinct examiners across 2 distinct art units. This indicates that while the company is engaging with multiple examiners, its technical focus is concentrated enough to remain within a limited number of administrative groups at the patent office.
The busiest examiner for the portfolio is SHIN, DANA H, who is assigned 1 pending office action. Since there are 3 pending office actions in total and 3 distinct examiners, the workload is evenly distributed among the individuals involved. The presence of 2 distinct art units suggests that the underlying technologies are closely related but distinct enough to be split between two specialized groups. Practitioners should look for consistency in the company's overall strategy while addressing the specific requirements of each examiner.
Because the busiest examiner, SHIN, DANA H, handles 1 pending office action, no single official dominates the prosecution of the Biotechnology & Pharmaceuticals portfolio. The use of 3 distinct examiners across 2 distinct art units requires a coordinated approach to ensure that arguments made in one case do not conflict with those in another. This distribution provides multiple points of contact with the patent office, reducing the impact of any single examiner's specific tendencies on the overall success of the company's filings.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHIN, DANA H | 1 | 26.9% | +26.9% |
| MCLEOD, AFRICA MHAIRIE | 1 | 52.8% | +67.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18287118 | GENE EXPRESSION REGULATORY SYSTEM USING CRISPR SYSTEM | SHIN, DANA H | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18287118 | GENE EXPRESSION REGULATORY SYSTEM USING CRISPR SYSTEM | SHIN, DANA H | — |
| 18030418 | ENGINEERED GUIDE RNA COMPRISING U-RICH TAIL FOR OPTIMIZED CRISPR/CAS12F1 SYSTEM AND USE THEREOF | MCLEOD, AFRICA MHAIRIE | — |
| Art Unit | Apps |
|---|---|
| 1635 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18287118 | GENE EXPRESSION REGULATORY SYSTEM USING CRISPR SYSTEM | SHIN, DANA H | 1635 | §103§112DP | Non-Final OA | — | Pending | Oct 16, 2023 |
| 18030418 | ENGINEERED GUIDE RNA COMPRISING U-RICH TAIL FOR OPTIMIZED CRISPR/CAS12F1 SYSTEM AND USE THEREOF | MCLEOD, AFRICA MHAIRIE | 1635 | §112DP | Non-Final OA | — | Pending | Apr 05, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGenkore Inc. has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Dana H Shin has the most, with 1 of Genkore Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
